Tesamorelin

Based on the available evidence, the safety profile of tesamorelin appears to be primarily documented in specific populations, particularly HIV patients with lipodystrophy. However, comprehensive safety data across broader populations is limited in the provided evidence.

Known Side Effects

The evidence provided does not contain detailed information about specific adverse events or their frequencies. One clinical case report mentions tesamorelin as a therapeutic option for visceral abdominal fat in HIV patients, but specific side effect profiles are not described in the available abstracts.

Contraindications

No specific contraindications are detailed in the provided evidence. This represents a significant gap in the available safety information.

Drug Interactions

The provided evidence does not contain information about drug-drug interactions with tesamorelin. This is a notable limitation in assessing the safety profile.

Populations That Should Avoid It

Based on the limited evidence provided:

• The available studies focus primarily on HIV-positive patients, suggesting the primary investigated use is in this population
• One withdrawn clinical trial (NCT02931474) involved service members with traumatic brain injury and insomnia, but the study was discontinued for unspecified reasons
• Safety in pregnant women, children, or patients with specific comorbidities is not addressed in the available evidence

Evidence Limitations

The safety evidence is notably thin in several critical areas:

• No detailed adverse event profiles or frequencies are provided
• Contraindication information is absent
• Drug interaction data is not available
• Long-term safety data is not presented in the abstracts
• Safety across diverse populations beyond HIV patients is not well-documented

Clinical Context

The available evidence suggests tesamorelin has been studied in clinical trials spanning Phase 1 and Phase 2 studies, with several completed trials in HIV populations. However, one Phase 2 trial was withdrawn, though the reasons are not specified in the available information.

Disclaimer: This safety summary is based on limited evidence from study abstracts and trial listings. For comprehensive prescribing information, contraindications, and detailed safety profiles, healthcare providers should consult the full prescribing information and current clinical guidelines. Patients should not make treatment decisions based solely on this summary and should consult qualified healthcare professionals.